See more : Argosy Minerals Limited (ARYMF) Income Statement Analysis – Financial Results
Complete financial analysis of Chemomab Therapeutics Ltd. (CMMB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chemomab Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ComfortDelGro Corporation Limited (CDGLF) Income Statement Analysis – Financial Results
- Aben Resources Ltd. (ABNAF) Income Statement Analysis – Financial Results
- Coeptis Therapeutics Holdings, Inc. (COEPW) Income Statement Analysis – Financial Results
- Bruush Oral Care Inc. (BRSHW) Income Statement Analysis – Financial Results
- cBrain A/S (0DWV.L) Income Statement Analysis – Financial Results
Chemomab Therapeutics Ltd. (CMMB)
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 66.83K | 57.77K | 34.02K | 80.00K | 281.91K | 66.00K | 51.00K | 40.64K | 26.25K | 0.00 |
| Gross Profit | -66.83K | -57.77K | -34.02K | -80.00K | -281.91K | -66.00K | -51.00K | -40.64K | -26.25K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.38M | 16.98M | 6.33M | 4.68M | 13.35M | 7.51M | 6.23M | 2.34M | 5.96M | 15.72M |
| General & Administrative | 7.08M | 11.56M | 6.03M | 1.29M | 960.00K | 374.00K | 0.00 | 0.00 | 0.00 | 5.65M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 5.96M | 5.08M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.08M | 11.56M | 6.03M | 1.29M | 5.98M | 5.46M | 3.11M | 2.25M | 1.14M | 5.65M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 749.00K | 3.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.46M | 28.53M | 12.37M | 5.97M | 19.33M | 12.97M | 9.34M | 4.59M | 7.11M | 21.37M |
| Cost & Expenses | 25.46M | 28.53M | 12.37M | 5.97M | 19.61M | 13.04M | 9.39M | 4.63M | 7.13M | 21.37M |
| Interest Income | 1.23M | 351.62K | 65.00 | 20.00K | 393.00K | 0.00 | 1.00K | 521.00 | 1.03K | 0.00 |
| Interest Expense | 0.00 | 353.00K | 111.08K | 6.00K | 9.00K | 0.00 | 5.00K | 0.00 | 14.16K | 0.00 |
| Depreciation & Amortization | 67.00K | 57.77K | 34.02K | 80.00K | 281.91K | 66.00K | 51.00K | 40.64K | 26.25K | 0.00 |
| EBITDA | -25.39M | -28.48M | -12.33M | -5.95M | -26.92M | -13.36M | -9.50M | -4.57M | -7.46M | 24.18M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -25.46M | -28.53M | -12.40M | -5.97M | -19.61M | -13.04M | -9.39M | -4.63M | -7.13M | 24.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.24M | 353.00K | -111.00K | 21.00K | -7.60M | -455.52K | -164.63K | 20.69K | -367.79K | 29.24M |
| Income Before Tax | -24.22M | -28.18M | -12.48M | -5.95M | -27.21M | -13.49M | -9.48M | -4.60M | -7.50M | 24.18M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -534.00K | 77.00K | -21.00K | 1.00 | 306.00K | 323.00K | 136.24K | -3.00 | 0.00 |
| Net Income | -24.22M | -27.65M | -12.56M | -5.93M | -27.21M | -13.80M | -9.81M | -4.73M | -7.50M | 24.18M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.06 | -2.43 | -1.21 | -3.20 | -15.80 | -21.84 | -217.31 | -17.42 | -32.94 | 0.00 |
| EPS Diluted | -2.06 | -2.43 | -1.21 | -3.20 | -15.80 | -21.84 | -217.31 | -17.42 | -32.94 | 0.00 |
| Weighted Avg Shares Out | 11.75M | 11.38M | 10.37M | 1.85M | 1.72M | 631.70K | 45.13K | 271.67K | 227.69K | 50.11B |
| Weighted Avg Shares Out (Dil) | 11.75M | 11.38M | 10.37M | 1.85M | 1.72M | 631.70K | 45.13K | 271.67K | 227.69K | 50.11B |
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will...
Chemomab (CMMB) Stock Gains 30% on FDA Clearance
There's potentially positive news for the medical community as well as investors of Chemomab (NASDAQ: CMMB ) today. CMMB stock is moving higher because Chemomab has good news on the regulatory front, plus the company expects to move forward with...
Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment
Shares of Chemomab Therapeutics Ltd. CMMB, -0.51% shot up 46.9% in premarket trading Tuesday, after the Israel-based biotechnology company said the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application to evaluate its systemic sclerosis (SSc) treatment,...
Chemomab Therapeutics Ltd. (CMMB) Q3 2022 Earnings Call Transcript
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Don Marvin - Chief...
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
TEL AVIV, Israel , Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company...
Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q2 2022 Results - Earnings Call Transcript
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer David Weiner - Interim Chief...
Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update
TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced...
Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference
TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management...
Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q1 2022 Results - Earnings Call Transcript
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & CEO David Weiner - Interim CMO Don...
New Strong Sell Stocks for March 14th
AVYA, BGS, and CMMB have been added to the Zacks Rank #5 (Strong Sell) List on March 14, 2022.
Source: https://incomestatements.info
Category: Stock Reports